Handbook of Juvenile Idiopathic Arthritis

<div>Introduction&nbsp;</div><div>Disease overview</div><div>Epidemiology</div><div>Etiology and pathogenesis</div><div>Environmental factors</div><div>Genetic susceptibility</div><div>Role of humoral and cell-mediated immunity</div><div>Pathogenesis of systemic arthritis</div><div>Pathophysiology of macrophage activation syndrome</div><div><br></div><div>Disease classification&nbsp;</div><div>Classification criteria&nbsp;</div><div>Challenges in classification</div><div><br></div><div>Clinical manifestations&nbsp;</div>Systemic arthritis&nbsp;<div>Rheumatoid factor-negative polyarthritis&nbsp;</div><div>Rheumatoid factor-positive polyarthritis&nbsp;</div><div>Oligoarthritis&nbsp;</div><div>Enthesitis-related arthritis&nbsp;</div><div>Psoriatic arthritis&nbsp;</div><div>Undifferentiated arthritis&nbsp;</div><div><br></div><div>Diagnosis&nbsp;</div><div>Clinical assessment&nbsp;</div><div>Imaging&nbsp;</div><div><div>Biomarkers&nbsp;</div><div>Differential diagnosis</div><div><br></div><div>Consequences and complications&nbsp;</div><div>Disease course of different subtypes&nbsp;</div></div>Skeletal and growth abnormalities&nbsp;<div>Ophthalmologic complications&nbsp;</div><div>Macrophage activation syndrome&nbsp;</div><div><br></div><div>General treatment aspects</div><div>Goals of treatment&nbsp;</div><div>Measuring treatment response&nbsp;</div><div>Treatment recommendations&nbsp;</div><div>A multidisciplinary approach to treatment&nbsp;</div><div>Special considerations in the pediatric patient&nbsp;</div><div><br></div><div>Management of patients with </div>juvenile&nbsp;idiopathic arthritis&nbsp;<div>Psychosocial factors&nbsp;</div><div>Physical therapy&nbsp;</div><div>Other non-pharmacologic interventions&nbsp;</div><div>Non-steroidal anti-inflammatory drugs&nbsp;</div><div>Intra-articular corticosteroids&nbsp;</div><div>Systemic corticosteroids&nbsp;</div>Conventional disease-modifying anti-rheumatic drugs&nbsp;<div>Biologic disease-modifying anti-rheumatic drugs&nbsp;</div><div>Safety of biologics&nbsp;</div><div>Other pharmacologic interventions&nbsp;</div><div>Management of iridocyclitis&nbsp;</div><div>Management of macrophage activation syndrome&nbsp;</div><div><br></div><div><div>Specific issues&nbsp;</div><div>Health-related quality of life&nbsp;</div><div>Vaccination&nbsp;</div><div>Treatment discontinuation after disease remission</div><div>Transition to adult care</div><div><br></div><div>Outcome, prognosis and future outlook&nbsp;</div><div>Long-term outcome and its prediction&nbsp;</div><div>Mortality&nbsp;</div><div>Future outlook&nbsp;</div><div>&nbsp; &nbsp; &nbsp;</div></div>